Clinical trial NCT01725958: Effects of a Nutritional Supplement Combination on Body Weight Management
Official title: A Phase IV, Open-label, Parallel Group, Single-Center Study on the Effects of a Nutritional Supplement Combination on Body Weight Management Over a 90-day Period
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Safety/Effacy
Lead sponsor: Pharmanex
Sponsor class: INDUSTRY
Collaborators: name: Nu Skin Enterprises
First posted: 2012-11-14
Enrollment: 60
Sex: ALL
Minimum age (years): 25
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Title: A Phase IV, Open-label, Single-Center Study on the Effects of a Nutritional Supplement Combination on Body Weight Management over a 90-day period

Detailed description: Safety assessment:

Safety will be assessed by changes in blood chemistries/hematology, and adverse events, of nutritional supplement emergent AEs (TEAEs), classified by severity grade, relatedness to the nutritional supplement.

Efficacy Assessment:

The objectives of this study are to evaluate the efficacy (changes in body composition and measurements as well as influence on appetite and quality of life changes) of the nutritional supplement administered repeatedly throughout the study.

Study Subject Population:

Healthy adult men and women are eligible for participation upon fulfillment of the inclusion/exclusion criteria.

Eligibility criteria: Inclusion Criteria:

1. Females and Males aged 25-65 years
2. Signed informed consent
3. BMI between 25 and 40 kg/m2
4. A resting normotensive blood pressure is defined as a systolic blood pressure between 90-145 mmHg and a diastolic blood pressure of 50 90 mmHg
5. Use of effective method of contraception by females of childbearing \[potential and agreement to continue to practice an acceptable method of contraception for the duration of their participation in the study\]. Acceptable methods of contraception include oral, injectable, or implantable contraceptives; intrauterine devices, diaphragm plus spermicide; abstinence (must agree to use double-barrier method if they become sexually active), transdermal patch, or any double barrier method including a vasectomized sexual partner. Women who have had a hysterectomy or tubal ligation at least 6 months prior to Visit 1 or who have been post-menopausal
6. Ability to speak and understand English
7. Willing to fast the morning of visit where blood samples are taken

Exclusion Criteria:

1. Self-reported chronic condition that may affect subject safety (e.g., diabetes, cardiovascular disease) or significantly impact product effectiveness (e.g., chronic fatigue)
2. Pregnancy/suspected pregnancy, breastfeeding or planning to become pregnant during the course of the study.
3. Use of Antihypertensive medication for less than 4 months or unregulated clinically blood pressure.
4. Having undergone gastroplasty or bariatric surgery in the past 10 years.
5. Taking medication (e.g., thyroid medication), must be stable for at least four months.
6. Allergies to any ingredients contained in the Nutritional Supplement.
7. Medical treatment for insomnia or depression within 30-days prior to the screening visit.
8. Tobacco (e.g. cigarettes, chewing tobacco, pipe, nicotine patches) use within 30-days prior to the screening visit.
9. Planned surgical procedure during the course of the study.
10. Currently participating in another study or have done so within 30 days prior to the screening visit or is likely to enroll in another clinical or nutritional study.
11. Currently taking any medication or supplement for the use of weight loss must be discontinued prior to Visit 1 Baseline Day 0.
12. Currently participating in a weight loss program or participated in a weight loss program in the past 6 months.

Primary outcomes:
measure: -Evaluate the changes in body composition as determined by percent body fat using the Bod Pod
timeFrame: 90 Days
Secondary outcomes:
measure: Evaluate the changes in body weight
timeFrame: 90 days
Other outcomes:
Locations:
city: Orem
country: United States
facility: Aspen Clinical Research
state: Utah
Study officials:
affiliation: Pharmanex
name: Steve Poole, BS
role: STUDY_DIRECTOR
References: